Approved for DENGVAXIA ® (Dengue Tetravalent Vaccine, Live) is a vaccine indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3, and 4. DENGVAXIA is approved for use in individuals 6 through 16 years of age with laboratory-confirmed previous dengue infection and living in endemic areas.. Following administration, DENGVAXIA elicits dengue-specific immune responses…
Loading full data from Know Your Drugs Institute…